BioSenic, a company specializing in serious autoimmune /inflammatory diseases and cell repair, has appointed Michel Wurm, MD, as interim Chief Medical Officer (CMO), responsible for the development of both of BioSenic’s cell therapy and autoimmune disease platforms.   Wurm replaces Anne Leselbaum as interim CMO and as an independent consultant. His appointment will commence with immediate effect. Both Wurm and Leselbaum worked and collaborated closely together alongside the medical and scienti...